NASDAQ:GLYC - GlycoMimetics, Inc.
$9.78
 $-1.39
-12.44%
4:00PM EDT
2019-07-22
GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  GLYC     avg for
industry  
  avg for
sector  
42 stocks weight:  25. 75   217. 37   399. 45  
42 stocks rank:  2. 98 K 1. 27 K 716. 99  
# analyst opinions:  5. 00   13. 21   13. 71  
mean recommendation:  1. 70   2. 10   2. 04  

quick ratio:  23. 59   5. 49   1. 88  
current ratio:  23. 88   5. 87   2. 36  

target price low:  19. 00   83. 44   114. 90  
target price avg:  21. 80   106. 20   137. 90  
target price high:  24. 00   132. 30   158. 97  
1-yr high:  16. 90   111. 86   142. 57  
last close:  11. 17   86. 79   125. 44  
50-day avg:  11. 82   86. 68   122. 63  
200-day avg:  11. 83   89. 22   121. 38  
1-yr low:  8. 47   69. 78   100. 51  
volume:  632. 80 K 2. 62 M 3. 43 M
50-day avg volume:  295. 91 K 3. 20 M 4. 16 M
200-day avg volume:  271. 00 K 2. 99 M 4. 75 M

1-day return:  -5. 98 % -1. 30 % -0. 99 %
this week return:  -11. 77 % 0. 45 % -0. 20 %
12-wk return:  -14. 08 % 0. 94 % 4. 84 %
52-wk return:  -29. 70 % -1. 30 % 10. 55 %

enterprise value (EV):  290. 85 M 45. 10 B 122. 38 B
market cap:  482. 33 M 38. 96 B 108. 40 B
EBITDA:  -54. 48 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  -5. 34   5. 38   11. 93  
total debt:  4. 08 M 10. 90 B 17. 48 B
debt/equity:  2. 12   57. 18   120. 05  
net income (common):  -50. 84 M 2. 07 B 4. 05 B

shares outstanding:  43. 18 M 538. 09 M 1. 24 B
shares:  33. 48 M 548. 00 M 1. 22 B
shares short:  5. 36 M 10. 98 M 11. 87 M
shares short prior month:  5. 52 M 9. 32 M 12. 05 M
short ratio:  25. 72   5. 60   3. 34  
short % of float:  22. 86 % 6. 48 % 2. 64 %
total cash/share:  4. 53   10. 98   9. 19  
total cash:  195. 56 M 5. 93 B 6. 10 B
free cash flow:  -29. 57 M 2. 92 B 4. 55 B
operating cash flow:  -47. 47 M 3. 80 B 5. 78 B

book value:  4. 46   13. 35   27. 45  
price/book:  2. 50   4. 60   8. 78  
operating margins:  0. 00 % -308. 40 % -28. 55 %
EBITDA margins:  0. 00 % 13. 17 % 23. 38 %
profit margins:  0. 00 % 10. 44 % 14. 18 %
gross margins:  0. 00 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  -1. 18   2. 10   4. 23  
forward EPS:  -1. 25   3. 45   7. 10  
P/E:  -9. 46   1. 90   32. 10  
forward P/E:  -8. 94   6. 46   15. 47  
PE/G:  1. 25   0. 70   -0. 54  
growth:  -7. 58 % 265. 63 % 79. 11 %
earnings high:  -0. 33   0. 89   1. 68  
earnings avg:  -0. 36   0. 70   1. 57  
earnings low:  -0. 40   0. 46   1. 46  
revenue high:  -0. 00   2. 57 B 11. 07 B
revenue avg:  -0. 00   2. 51 B 10. 91 B
revenue low:  -0. 00   2. 45 B 10. 73 B
return on assets:  -15. 15 % -2. 34 % 5. 28 %
return on equity:  -23. 60 % -90. 08 % 133. 53 %

beta (1yr vs S&P500):  1. 68   1. 27   0. 91  
sharpe (1yr):  -0. 48   0. 16   0. 77  

held % insiders:  1. 31 % 6. 06 % 3. 29 %
held % institutions:  106. 17 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : GLYC
.    114.151 =       114.151 :: --> INITIAL WEIGHT <--
.    - 1.181 =        112.97 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.247 =       253.889 :: P/E factor
.     x 0.98 =       248.912 :: PE/G factor
.    x 1.558 =       387.737 :: beta factor
.    x 0.812 =       314.902 :: sharpe factor
.    x 4.081 =      1285.239 :: current ratio factor
.    x 1.022 =      1313.384 :: quick ratio factor
.    x 1.019 =      1338.673 :: short ratio factor
.    x 1.013 =      1356.043 :: price-to-book factor
.    x 1.018 =      1380.916 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =      2928.638 :: sector+industry 1-year gains factor
.    x 1.009 =      2956.249 :: industry 12-weeks return factor
.    x 1.308 =      3866.444 :: industry 2-weeks return factor
.    x 0.928 =      3588.093 :: company one-year gains+dividend factor
.    x 2.485 =      8915.947 :: company 13 weeks' performance factor
.    x 1.063 =      9477.379 :: 5-day avg > 200-day avg
.    x 1.135 =      10759.63 :: 5-day avg > 50-day avg
.    x 0.982 =     10564.576 :: "drift" penalty 3 days ago
.    x 0.976 =     10314.634 :: "drift" penalty 4 days ago
.     x 0.97 =     10000.882 :: "drift" penalty 5 days ago
.    / 1.964 =      5091.359 :: overall "drift" factor
.    x 0.866 =      4407.786 :: largest single-day jump factor
.    x 0.166 =       733.409 :: low price factor
.    x 1.079 =        791.54 :: notable returns + performance factor
.    x 3.351 =      2652.275 :: inverse volume-to-price factor
.                               --> PROJECTIONS <--
.    x 0.931 =      2470.422 :: forward EPS factor
.    x 0.975 =      2408.871 :: forward P/E factor
.    x 1.185 =      2853.819 :: industry recommendation factor
.    x 2.505 =       7149.36 :: company recommendation factor
.    x 1.003 =      7169.131 :: factor historical industry gain for week 29
.    x 2.039 =     14616.343 :: target low factor
.    x 1.325 =     19369.231 :: target mean factor
.    x 1.045 =     20241.094 :: target high factor
.   x 11.193 =    226566.493 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        21.817 :: reduced for readability
.    + 3.937 =        25.754 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     25.754 :: FINAL WEIGHT for NASDAQ:GLYC


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org